George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension Novel proprietary triple low-dose combination pill has been shown to outperform traditional blood pressure treatments without additional side effects in earlier clinical research Lead candidate in Company’s pipeline of proprietary fixed-dose combination therapies targeting high unmet need in large patient populations suffering from non-communicable diseases such as CVD and Diabetes London, UK, 1 July 2021 – George Medicines, a late-stage drug development company focused […]